



**FOR IMMEDIATE RELEASE**

## **SPARC Completes Enrolment in PROSEEK, A Global Phase 2 Study of Vodobatinib in Early Parkinson's Disease**

- *506 patients completed enrolment across 84 sites in the US, Europe & India*
- *PROSEEK is one of the largest Phase 2 study in patients with early Parkinson's disease*

**MUMBAI, India October 30, 2023**, Sun Pharma Advanced Research Company Ltd. (SPARC)(Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced the completion of enrolment of 506 patients in a global, randomized, double-blind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706 (PROSEEK).

"This is a significant milestone for SPARC & Vodobatinib. I would like to express my gratitude to all the patients, caregivers and the physicians associated with PROSEEK." said Anil Raghavan, CEO of SPARC.

### **About PROSEEK:**

PROSEEK is global, randomized, double-blind, placebo-controlled Phase 2 study in patients with early Parkinson's disease evaluating the safety and efficacy of Abl tyrosine kinase inhibition using K0706/SCC-138.

The primary endpoint is the change from baseline to week 40 in the score of the MDS-UPDRS Part III (Movement Disorder Society – Unified Parkinson's Disease Rating Scale).

The key secondary endpoints include:

- Change from baseline to Week 40 in the sum of the MDS-UPDRS Parts II and III total scores
- Time from baseline to initiation of symptomatic medication
- Change in health-related quality of life as measured by the European quality of life questionnaire
- Change in Clinician global impression of severity

### **About Vodobatinib (SCC-138/K0706):**

Vodobatinib is a potential first-in-class, highly selective and brain penetrating c-Abl inhibitor. Vodobatinib is being evaluated under multiple clinical trials in patients with Parkinson's disease, Dementia with Lewy Body and Chronic Myelogenous Leukemia.

### **About SPARC (CIN: L73100GJ2006PLC047837):**

Sun Pharma Advanced Research Company Ltd. ('SPARC') is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the Company can be found at [www.sparc.life](http://www.sparc.life).

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.  
Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: [www.sparc.life](http://www.sparc.life)

Registered office : Plot no. 5&6/1, Savli GIDC Estate, Manjusar 391775, District: Vadodara, Gujarat, India.



**Disclaimer:**

Statements in this document describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

**Media Contact:**

Jaydeep Issrani  
Tel +91 22 66455645, Extn: 5787  
Tel Direct +91 22 6645 5787  
Mobile +91-9820216916  
E mail [jaydeep.issrani@sparcmail.com](mailto:jaydeep.issrani@sparcmail.com)

®, TM - All brand names and trademarks are the property of respective owners.